Close Menu

UCSF

The company's DETECTR disease detection platform will be used to help develop the technology and optimize the CRISPR enzymes used in the point-of-care device.

The contract was awarded under DARPA's Detect It with Gene Editing Technologies program, which aims to create a device to detect at least 10 pathogens.

The two new tests, which have the capability to quantify a patient's viral load, have been designed without external RNA extraction or amplification steps.

The company believes its tests can already help oncologists better assess post-surgery risk, though prospective validation would be necessary for broad claims.

The approach, which is developed for both Illumina and nanopore sequencing, had high sensitivity and specificity for identifying bacteria and fungi.

In Nature this week: CRISPR-Cas3 system for making large deletions efficiently, more.

Synthego has developed an off switch for CRISPR by engineering a guide RNA that can be controlled through exposure to UV light.

Almost As Good

A small study has found that a rapid test for SARS-CoV-2 works about as well as a PCR test, according to the New York Times.

The study compared SARS-CoV-2 to SARS-CoV-1 and MERS to find viral commonalities, and combined the analyses with real-world clinical data to suggest treatments.

Researchers linked chromatin interactions, super-interactive promoters, and other regulatory features to specific cell types in the developing brain cortex.

Pages

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.